Hepatopulmonary syndrome (HPS) is a relatively common and potentially severe pulmonary complication of cirrhosis with increased risk of mortality. In experimental models, a complex interaction between pulmonary endothelial cells, monocytes, and the respiratory epithelium, which produces chemokines, cytokines, and angiogenic growth factors, causes alterations in the alveolar microvasculature, resulting in impaired oxygenation. Model systems are critical for evaluating mechanisms and for preclinical testing in HPS, due to the challenges of evaluating the lung in the setting of advanced liver disease in humans. This review provides an overview of current knowledge and recent findings in the rodent common bile duct ligation model of HPS, which recapitulates many features of human disease. We focus on the concepts of endothelial derangement, monocyte infiltration, angiogenesis, and alveolar type II cell dysfunction as main contributors and potential targets for therapy. (Hepatology 2018;68:2016-2028). P ulmonary vascular abnormalities, including diffuse or localized dilations of pulmonary precapillary and capillary vessels (intrapulmonary vascular dilations [IPVDs]) and intrapulmonary arteriovenous communications, are common in patients with advanced liver disease, with an estimated prevalence of 13%-57%.
P ulmonary vascular abnormalities, including diffuse or localized dilations of pulmonary precapillary and capillary vessels (intrapulmonary vascular dilations [IPVDs] ) and intrapulmonary arteriovenous communications, are common in patients with advanced liver disease, with an estimated prevalence of 13%-57%. (1, 2) Up to 30% of patients with cirrhosis and IPVDs develop abnormal gas exchange and hypoxemia, which is defined as hepatopulmonary syndrome (HPS). (3) Three mechanisms are responsible for impaired oxygenation of venous blood, resulting in hypoxemia. First, IPVDs lead to increased perfusion relative to local ventilation (V/Q mismatch), which may be exacerbated by impaired hypoxic pulmonary vasoconstriction. (4, 5) Second, an increased capillary diameter lengthens the distance oxygen molecules have to traverse to bind hemoglobin and may be exacerbated by the hyperdynamic circulation of cirrhosis (diffusion restriction). Third, direct arteriovenous communications allow blood to bypass pulmonary oxygenation, resulting in admixture of arterial and venous blood. HPS is associated with reduced quality of life and significant increases in mortality in affected patients. (3) Currently, liver transplantation is the only curative treatment, highlighting the need for effective medical therapies.
The development of medical therapies for HPS is dependent on preclinical studies using animal models that share features of human disease. Over the last two decades, a number of rodent models have been tested for the ability to recapitulate the pulmonary vascular and gas exchange abnormalities of human HPS, including common bile duct ligation (CBDL) cirrhosis, thioacetamide (TAA) cirrhosis, and isolated portal hypertension (PH) induced by partial portal vein ligation (PPVL). Of these models, CBDL in the rat is unique in mimicking the physiologic features of human HPS and has been the most studied. (6) More recently, the characterization of CBDL in the mouse as a model of HPS, which exhibits a slight difference in the time course of development of liver injury and HPS relative to the rat, adds significantly to the potential to study HPS pathogenesis. (7) During CBDL, the common bile duct is ligated and dissected, resulting in obstructive cholestasis, bile duct proliferation, hepatic inflammation, and periportal fibrosis. Within 1 week after CBDL, portal venous pressure begins to rise, followed shortly thereafter by the development of a hyperdynamic circulation. (8, 9) Intrapulmonary shunting and HPS develop by week 2, when bridging fibrosis is present in the liver, and worsen during the progression to a cirrhotic state. (6) (7) (8) Cirrhosis develops within 4 weeks in rats and 6 weeks in mice. (9) Similar to the human situation, experimental HPS does not require the presence of advanced cirrhosis to develop.
Four major pulmonary alterations (intrapulmonary vasodilation, intravascular monocyte infiltration, angiogenesis, and alveolar type II (AT2) cell dysfunction), drive gas exchange abnormalities in experimental HPS. This review summarizes recent progress in understanding the mechanisms for these alterations and in uncovering novel targets for therapy.
Pathogenesis of HPS: Lessons From Experimental Models

INtRapUlMoNaRy VasCUlaR dIlatIoNs
Vascular tone
A key feature of HPS is the development of IPVDs. One putative contributor is increased levels of exhaled nitric oxide (NO), a potent vasodilator, which are found in patients with cirrhosis and HPS and normalize as the syndrome resolves after liver transplantation. (10) (11) (12) Similar findings have been reported from experimental studies of HPS, where increased exhaled and intrapulmonary NO levels are found after CBDL. In this setting, NO inhibition with N-nitroarginine methyl ester (L-NAME) decreases intrapulmonary shunting and improves gas exchange. (13, 14) In vitro experiments, investigating the contractile response to phenylephrine, confirm that increased pulmonary NO production is responsible for decreased pulmonary vascular tone in experimental HPS. (15) The increase in pulmonary NO production results from both increased activity of endothelial NO synthase (eNOS), produced by the pulmonary microvascular endothelium, (16) and inducible NO synthase (iNOS), produced by infiltrating monocytes. Downstream, NO diffuses across the vascular smooth muscle cell membrane and activates the guanylate cyclase/cyclic guanosine monophosphate signaling pathway, leading to vascular relaxation. In this regard, intravenous aRtICle INFoRMatIoN: methylene blue, which blocks stimulation of guanylate cyclase by NO, has been used anecdotally to treat severe posttransplant hypoxemia in HPS patients. (17) 
endothelin-1-Induced endothelial dysfunction
Hepatic and plasma endothelin-1 (ET-1) levels increase beginning 1 week after CBDL in experimental HPS, in association with a subsequent (week 2 after CBDL) increase in pulmonary microvascular eNOS activity, development of IPVDs, and the onset of HPS. (8, 16, 18) ET-1 classically acts as a potent vasoconstrictor, including in the portal circulation where it increases sinusoidal and presinusoidal resistance. Paradoxically, circulating ET-1 specifically promotes vasodilation in the pulmonary circulation of CBDL rats. This differential effect of ET-1 depends on the expression of and binding to its receptors. The endothelin A and B (ET B ) receptors expressed by vascular smooth muscle cells mediate vasoconstriction, while the ET B receptor on endothelial cells up-regulates eNOS and NO, mediating vascular relaxation. (8) CBDL leads to a specific up-regulation of the endothelial ET B receptor, postulated to be driven by increased pulmonary shear stress derived from increased blood flow during the development of a hyperdynamic circulatory state. (19, 20) Selective inhibition of the ET B receptor ameliorates experimental HPS and confirms a central role of the ET-1/ET B /eNOS/NO pathway in modulating vasodilation. (8, 21) Interestingly, pulmonary ET B receptor levels are also increased in PPVL rats, although HPS does not develop in this model, where circulating ET-1 levels are not elevated. (8, 22) However, exogenous ET-1 can drive the development of HPS in PPVL animals. (20) Under normal circumstances, endothelial cells and stellate cells are the major hepatic cell types recognized to produce ET-1. (23) In the CBDL model, the major increase in hepatic ET-1 is derived from proliferating cholangiocytes and results in a selective increase in circulating ET-1 levels relative to other models (PPVL and TAA). (23) Elevated circulation of ET-1 then drives ET B receptor activation. (8, 18, 23, 24) Based on these observations, ET B receptor blockade may be of potential therapuetic benefit in HPS.
Monocyte Infiltration
A second contributor to NO production after CBDL is iNOS. Multiple studies have found increased pulmonary iNOS levels beginning 3 weeks after CBDL, produced by pulmonary intravascular monocytes which infiltrate the lung vasculature specifically after CBDL. (8, 13, (25) (26) (27) Macrophage depletion studies, using clodronate and gadolinium, confirm a reduction in iNOS and improved gas exchange and support the importance of intravascular monocyte influx in experimental HPS. (27) Infiltrating monocytes also express heme oxygenase-1 and produce carbon monoxide beginning 3 weeks after CBDL, which exerts additional vasodilator effects relative to NO. (8, 26) In human HPS, carboxyhemoglobin levels are increased relative to non-HPS patients with cirrhosis, consistent with increased carbon monoxide production in human disease. (28) Although the importance of pulmonary intravascular monocytes is recognized in experimental HPS, (13, 26, 27, 29) little is known about the origin, behavior, and phenotype of these cells. Recruited monocytes are generally considered to be derived from progenitor cells in the bone marrow that migrate to the site of injury. However, a recent study found that splenic reservoir monocytes contribute to pulmonary monocyte accumulation in experimental HPS. (30) Splenectomy decreased pulmonary monocyte influx and improved gas exchange but increased hepatic monocyte levels and significantly worsened liver function. (30) One trigger for pulmonary intravascular monocyte accumulation appears to be bacterial translocation from the gut into the portal circulation. In the setting of cirrhosis, including CBDL, intestinal bacterial overgrowth, disruption of the gut mucosal barrier, decreased clearance capacity of the liver, and the development of portosystemic shunts allow circulating endotoxins to enter the pulmonary circulation. (25, 27, 31, 32) Once in circulation, these bacterial products induce local production of chemotactic factors and cell adhesion molecules, guiding monocyte recruitment and adherence to the pulmonary endothelium. (25, 31, 33) Bacterial translocation, as reflected by culture-positive mesenteric lymph nodes, occurs in the majority of CBDL rats once cirrhosis develops and correlates with higher incidence and severity of HPS. (29, 31, 32) In contrast to CBDL, where endotoxemia correlates with HPS severity, plasma endotoxin levels are not elevated in PPVL-treated and TAAtreated rats where HPS does not develop. (24, 34, 35) Moreover, prophylactic norfloxacin treatment reduces experimental HPS severity and intrapulmonary monocyte recruitment in association with reduced translocation of gram-negative organisms. (29) Plasma concentrations of tumor necrosis factor alpha (TNFα), a proinflammatory cytokine secreted in response to inflammatory stimuli, including endotoxin exposure, are also increased in human and experimental cirrhosis and parallel circulating endotoxin levels. (24, 25) Prophylactic TNFα inhibition reduces the development of HPS features in CBDL rats. (25, 29, 36, 37) Both pentoxifylline, a nonspecific phosphodiesterase inhibitor known to reduce TNFα synthesis, and anti-TNFα antibodies appear to mitigate HPS through prevention or reduction of the development of the hyperdynamic circulation. (25, 37) Pentoxifylline administration in established experimental HPS also improves gas exchange by down-regulating pulmonary ET B receptor expression and subsequent eNOS-mediated NO production, without altering systemic or portal pressures. (36) In vitro experiments support that pentoxifylline inhibits ET B receptor expression by blocking shear stress-mediated up-regulation. (36) Chemotactic factors, up-regulated by inflammatory cytokines, regulate the recruitment and sequestration of monocytes to the pulmonary vascular bed. Increased pulmonary microvascular expression of fractalkine (CX3CL1) develops after 2 weeks of CBDL and attracts circulating monocytes that display the fractalkine receptor (CX3CR1) and increased chemokine (C-X-C motif ) receptor 2 (CXCR2), a common receptor for various chemokines. (38, 39) Early pulmonary vascular monocyte recruitment is also found in HPS mice, driven by elevated levels of monocyte chemoattractant protein 1, a main mediator for monocyte attraction, produced by both endothelial cells and macrophages. (7, 40) Blocking monocyte chemotaxis has been shown to be beneficial, with both CX3CR1 neutralizing antibodies and CXCR2 inhibition reducing intrapulmonary monocyte accumulation and improving experimental HPS. (38, 39) Downstream, CX3CL1 and CXCR2 signaling have been implicated in direct activation of the Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase and phosphoinositide 3-kinase/Akt/eNOS pathways in endothelial cells, promoting cell survival, proliferation, and angiogenesis. (38, 39) Furthermore, ET B receptor activation by ET-1 on the pulmonary microvascular endothelial cell augments CX3CL1 production, supporting a mechanistic link between the ET-1/ET B receptor axis and CX3CL1/CX3CR1 in mediating monocyte adhesion and angiogenesis in experimental HPS. (41) 
INtRapUlMoNaRy aRteRIoVeNoUs sHUNt FoRMatIoN
Several lines of evidence in experimental and human HPS support that vascular remodeling, endothelial dysfunction, and angiogenesis (new blood vessel formation from preexisting vessels) contribute to HPS development. In humans, single-nucleotide polymorphisms in genes involved in the regulation of angiogenesis, including endoglin (ENG) and von Willebrand factor (vWF), are associated with the risk of HPS; and circulating levels of these factors, as well as vascular cell adhesion molecule 1, are increased in serum of patients with cirrhosis and HPS compared to those without HPS. (7, 42, 43, 78) In CBDL animals, scanning electron microscopic evaluation of pulmonary vascular casts showed, in addition to crypts representing sites of intravascular macrophage adhesion, increased microvascular density and capillary diameter, along with signs of intussusceptive angiogenesis and the presence of direct vascular communications. (44) Later studies confirmed increased pulmonary expression of the endothelial markers vWF, vascular endothelial-cadherin, and ENG, supporting the importance of angiogenesis in microvascular proliferation and shunt formation in experimental HPS. (7, 45) Angiogenesis is mediated by angiogenic growth factors. Vascular endothelial growth factor A (VEGF-A, present at week 2), platelet-derived growth factor (PDGF, present at week 4), and placental growth factor (PlGF, present at week 2) are all angiogenic factors produced in part by intravascular monocytes and implicated in pulmonary angiogenesis in experimental HPS. These factors may serve as potential targets for therapy. (7, 27, 45) VEGF-A, PDGF, and PlGF stimulate cellular processes by binding to tyrosine kinase receptors on the cell surface. VEGF-A and PlGF belong to the VEGF family. VEGF-A binds to VEGF receptors 1 (VEGFR1) and 2 (VEGFR2), with VEGFR2 being responsible for proangiogenic signaling, while VEGFR1 functions as a decoy. (46) PlGF specifically binds to VEGFR1 and stimulates angiogenesis both indirectly by displacement of VEGF-A from VEGFR1, triggering VEGF/VEGFR2 signaling, and directly by VEGFR1 activation and stimulation of crosstalk between VEGFR1 and VEGFR2. (46) Administration of pentoxifylline, which reduces pulmonary monocyte infiltration, or delivery of recombinant adeno-associated virus-6 encoding human endostatin plus angiostatin, which directly blocks angiogenic pathways, down-regulated pulmonary angiogenesis and improved HPS in CBDL rats. (45) Treatment with sorafenib, a multispecific tyrosine kinase receptor inhibitor targeting the VEGF and PDGF receptor and Raf family kinases, also reduced the degree of shunting and improved gas exchange in HPS rats. (47) The beneficial effect of sorafenib may be attributed to at least three mechanisms. First, sorafenib might indirectly mitigate HPS by improving underlying liver injury, fibrosis, and PH. (48) Second, sorafenib directly targets the VEGF/VEGFR-2/Akt pathway and pulmonary angiogenesis in the pulmonary microvasculature in vivo and in rat pulmonary microvascular endothelial cells in vitro. (47, 48) Third, sorafenib blocks cholangiocyte proliferation and ET-1 production, resulting in decreased eNOS-mediated vasodilation. (48) Based on these preclinical data, a pilot randomized clinical trial (RCT) of sorafenib in human HPS has recently completed enrollment (NCT02021929).
The recent identification of PlGF as a central contributor to the development of HPS in mice parallels mechanisms in rat HPS and expands potential therapeutic targets. (7) In addition to up-regulation of VEGF signaling, PIGF has a direct prosurvival effect on endothelial cells and attracts VEGFR1-expressing macrophages and bone marrow progenitors, which further stimulate the angiogenic process by additional growth factor release. (46) Previous studies revealed that PlGF is not required for physiological vessel maintenance in healthy mice. (46, 49) However, in the setting of pathology, PlGF can drive angiogenesis. (46, 49) PlGF neutralization selectively inhibits pathological angiogenesis and does not cause significant side effects. (46, 49) Anti-PlGF monoclonal antibodies improve HPS in mice by counteracting pulmonary angiogenesis and by attenuating pulmonary monocyte influx. (7) Increased PlGF expression appears to be confined to the lung, predominantly in infiltrating monocytes and AT2 cells; and anti-PlGF therapy does not affect liver alterations, supporting its capacity to selectively target the pulmonary compartment. (7) Anti-PlGF antibody treatment represents an attractive drug candidate and has been found to be safe (49) and well tolerated in human healthy volunteers and oncologic patients. (50) (51) (52) Together, findings in rat and mouse HPS support that pulmonary angiogenesis is a key feature and an important potential therapeutic target in both situations and in humans. Moreover, angiogenesis in experimental HPS appears to be a consequence of both a pulmonary proinflammatory state, with infiltrating monocytes producing proangiogenic mediators, (7, 27, 45) as well as inflammatory and vasoactive mediators directly affecting the pulmonary endothelium. (53) (54) (55) (56) Therefore, a broad range of targets, including the gut microbiome, bacterial translocation, chemokine signaling, cell adhesion molecule expression, monocyte activation, as well as direct inhibition of vasoactive and angiogenic mediators, could have beneficial effects in human disease.
INVolVeMeNt oF tHe RespIRatoRy epItHelIUM
Generally, HPS has been considered to be disorder of the alveolar microcirculation, with definitions excluding both significant intrinsic lung disease and ventilation abnormalities. However, recent findings have challenged this view. For instance, it is well recognized that HPS may coexist with intrinsic lung abnormalities, although the two processes have been considered distinct. More recently, subtle pulmonary function test abnormalities including lower forced expiratory volume in the first second (FEV1) and forced vital capacity, with a preserved ratio between the two, have been observed in patients with cirrhosis and HPS compared to those without, supporting that ventilation defects may contribute to gas exchange abnormalities in HPS. (57) Similar findings are found in experimental HPS, where reductions in tidal volume, minute ventilation, and mean inspiratory flow rate, attributable to uneven distribution of alveolar ventilation and decreased mean alveolar cord length reflecting alveolar collapse, have been found. (58) These functional and structural alveolar alterations are associated with increased apoptosis of AT2 cells and a resultant decrease in surfactant protein (SP) production (SP-A, B, C, D). (57, 59) Surfactant, a lipoprotein complex formed by AT2 cells, maintains alveolar integrity, prevents collapse, and regulates lung injury and inflammation. Elevated circulating bile acid and TNFα levels, found after CBDL, may contribute to effects on AT2 (57) Moreover, AT2 cell integrity and SP production are maintained in PPVL animals, in which circulating bile acids and TNFα levels are not elevated. Interestingly, serum bile acids are significantly increased in patients with cirrhosis and HPS compared to patients without HPS. (60) These observations, together with our knowledge that experimental HPS exclusively develops in a model of cholestatic liver disease and not following PPVL or TAA, suggests that altered bile acid signaling may contribute to HPS development. The mechanistic link between cholestasis, AT2 cell dysfunction, and HPS has not been unraveled yet and is currently the subject of further investigation. Lastly, pulmonary monocyte influx, which has been associated with reduced SP production in other pulmonary disorders, might also result in the production of mediators that influence alveolar integrity. (61, 62) Results from preclinical studies in HPS are summarized in Table 1 . Figure 1 illustrates our current understanding of HPS pathogenesis.
Human Studies in HPS
Despite significant progress in fundamental HPS research, effective pharmacological therapies are currently lacking. Small human studies reporting on the use of L-NAME, norfloxacin, and pentoxifylline, agents that have been proven effective in experimental HPS, had contradictory results (Table 2) . (63) (64) (65) (66) (67) (68) (69) (70) Other drugs, including mycophenolate mofetil, paroxetine, iloprost, somatostatin, almitrine, and cyclooxygenase inhibitors, have been empirically tried in small studies and did not show a clear benefit. (71) Improvement of gas exchange was documented in three studies in which HPS patients were treated with garlic, which has been reported to have antiangiogenic activity and is known to alter the gut microbiome, two components that are implicated in experimental HPS pathogenesis. (72) (73) (74) However, it is difficult to draw clinical conclusions from the small number of included patients. To fully assess new therapies, larger multicenter clinical trials will be needed. Table 3 gives an overview of potential interventions for therapy, derived from findings in experimental HPS, grouped based on risk to benefit ratio. Angiogenesis inhibition and gut decontamination are relatively low-risk strategies with potential benefit. Tyrosine kinase inhibitors are potent antiangiogenic agents and have a track record of chronic use in patients with cirrhosis and HCC, where reductions in portosystemic shunts have been observed. (75) One multicenter pilot RCT assessing the effects of sorafenib in HPS has just completed enrollment (NCT02021929). Although generally well tolerated, tyrosine kinase inhibitor toxicity may be significant; and they are not approved in Child-Pugh class C patients. Anti-PlGF antibodies, which selectively inhibit pathological vessel formation, are anticipated to have less off-target toxicity and may represent a more attractive therapeutic strategy. Intestinal decontamination, aimed at decreasing endotoxemia, might reduce pulmonary inflammation and may be beneficial. In one human study, norfloxacin failed to improve gas exchange. (67) Abbreviations: HCV, hepatitis C virus; IV, intravenously; L-NAME, L-Nitroarginine methyl ester; Neb, nebulized; PTX, pentoxifylline.
Potential New Therapeutic Strategies in HPS
this situation it is not defined whether the opposing vasoconstrictive and vasodilatory actions of the receptor types would lead to improvement in the setting of HPS. Moreover, mixed ET receptor antagonists may have hepatic toxicity (LiverTox.nlm.nih.gov). (76) Caspase inhibitors have been used in therapeutic trials in hepatic fibrosis and PH and are generally well tolerated. However, the pulmonary effects of these agents would be anticipated to target AT2 cell alterations and not the vascular abnormalities of HPS and are therefore unlikely to be effective as primary therapy. TNF inhibition might have beneficial effects in HPS but is considered high risk. In two small pilot human studies of HPS, TNF inhibition with pentoxifylline had conflicting results on gas exchange. (68) (69) (70) In one of these studies, pentoxifylline was poorly tolerated. (70) Currently available potent biologic TNF inhibitors are generally avoided in decompensated liver diseases as they may cause hepatotoxicity, may increase risk of infection, and may be associated with reactivation of hepatitis B. (77) Finally, a number of agents are considered to have low or unknown risk, with uncertain potential benefit. For example, modulating the circulating bile acid pool or supplementing surfactant could mitigate AT2 cell dysfunction. However, such a strategy, similar to caspase inhibition, would be anticipated to have a limited impact on the vascular alterations in HPS. Pharmacological inhibition of the chemokine receptors CX3CR1 and CXCR2 could inhibit intravascular monocyte accumulation and improve HPS. Such an approach has parallels in ongoing trials of chemokine receptor antagonists in human liver disease (NCT02217475, NCT0265362, NCT03059446, NCT03028740). Challenges include the high degree of redundancy in chemokine networks and the 
Conclusion
Over the past several decades, the clinical importance of liver-lung interactions in chronic liver disease, specifically the entity of HPS, has been widely appreciated. The CBDL experimental model has provided a pathogenic framework to explore mechanisms of human disease. Impaired gas exchange in experimental HPS involves both vascular (perfusion) and alveolar (ventilation) defects and is driven by ET-1-mediated endothelial dysfunction, endotoxemia with subsequent intrapulmonary monocyte recruitment, pathological angiogenesis, and AT2 cell dysfunction. Future priorities will be to identify links between experimental and human disease and to organize multicenter RCTs, trialing individual and combined treatments, directed at pathophysiological targets identified in preclinical studies.
